Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

ConclusionIntegrated PK/PD, safety, and efficacy data support 240  mg/m2 as the RP2D for trilaciclib.ClinicalTrials.gov IdentifiersNCT02243150; NCT02499770; NCT02514447.

Source: Cancer Chemotherapy and Pharmacology - February 17, 2021 Category: Cancer & Oncology Source Type: research